ReviewCurrent rheumatology reports2014
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
Review in Current rheumatology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.Annals of the rheumatic diseases · 2017Guideline
- ANA fluorescence patterns and low C4 are associated with higher antiphospholipid antibody serological intensity in routine diagnostic testing.Clinical chemistry and laboratory medicine · 2026Article
- Burden, causes, and treatment approaches of recurrent pregnancy loss: a scoping review.The Pan African medical journal · 2025Article
- Patients with DVT and primary antiphospholipid syndrome have worse obstetric outcomes than pregnant women with DVT and negative antiphospholipid antibodies: a retrospective cohort study.Sao Paulo medical journal = Revista paulista de medicina · 2025Article
- Vitamin D in Lupus Patients of Childbearing Age: Are We Doing Enough?Frontiers in reproductive health · 2022Review
- Dendritic Cells and Antiphospholipid Syndrome: An Updated Systematic Review.Life (Basel, Switzerland) · 2021Review
- Placental contribution to neonatal encephalopathy.Seminars in fetal & neonatal medicine · 2021Review
- Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome.Molecules (Basel, Switzerland) · 2021Article
- Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China.Clinical rheumatology · 2019Article
- Effectiveness of high-dose i.v. immunoglobulin therapy for pregnant women with aspirin-heparin-resistant secondary antiphospholipid syndrome.Reproductive medicine and biology · 2018Article
- Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2018Article
- Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.Arthritis & rheumatology (Hoboken, N.J.) · 2017Review
- Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.Clinical reviews in allergy & immunology · 2017Review
- Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion.Chinese medical journal · 2017Article
- Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8.Molecular human reproduction · 2016Article
- Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.International journal of hematology · 2016Review
- Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.American journal of obstetrics and gynecology · 2016Article
- Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with persistently circulating antiphospholipid antibodies (aPL) have a higher incidence of recurrent abortions, fetal losses, pre-eclampsia, and placental insufficiency. Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events. In addition to the classical thrombotic placental events, other factors involving inflammation and complement activation seem to play a role in certain complications. In this article, we will review how medications interfere in the pathogenic mechanisms of APS, discuss the impact of current recommended treatment on pregnancy morbidity, and analyze new promising therapies.
Indexed as
Identifiers
24390757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.